Sionna Therapeutics (NASDAQ:SION) Director Peter Thompson Sells 184,639 Shares

Sionna Therapeutics, Inc. (NASDAQ:SION) Director Peter Thompson sold 184,639 shares of the stock in a transaction on Monday, May 11th. The shares were sold at an average price of $46.22, for a total transaction of $8,534,014.58. Following the completion of the transaction, the director owned 2,671,822 shares of the company’s stock, valued at approximately $123,491,612.84. This represents a 6.46% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Sionna Therapeutics Price Performance

Shares of NASDAQ:SION traded up $1.72 during midday trading on Monday, reaching $45.95. 670,726 shares of the company’s stock were exchanged, compared to its average volume of 474,065. The company’s 50 day simple moving average is $38.55 and its two-hundred day simple moving average is $39.36. Sionna Therapeutics, Inc. has a 12 month low of $11.77 and a 12 month high of $48.45.

Sionna Therapeutics (NASDAQ:SION) last posted its earnings results on Monday, March 2nd. The company reported ($0.46) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.61) by $0.15. As a group, equities research analysts anticipate that Sionna Therapeutics, Inc. will post -2.32 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on SION shares. Lifesci Capital raised Sionna Therapeutics to a “strong-buy” rating in a report on Wednesday, February 25th. UBS Group reiterated a “buy” rating on shares of Sionna Therapeutics in a research report on Monday, March 2nd. JonesTrading increased their price objective on Sionna Therapeutics from $52.00 to $63.00 and gave the stock a “buy” rating in a research note on Tuesday, April 28th. Guggenheim lifted their price objective on Sionna Therapeutics from $45.00 to $50.00 and gave the company a “buy” rating in a report on Monday, March 2nd. Finally, BTIG Research restated a “buy” rating and issued a $58.00 target price on shares of Sionna Therapeutics in a research note on Monday, April 27th. Three investment analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating and two have issued a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $53.00.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the company. GF Fund Management CO. LTD. bought a new stake in Sionna Therapeutics during the 4th quarter worth approximately $36,000. Russell Investments Group Ltd. bought a new position in Sionna Therapeutics in the 3rd quarter valued at $30,000. Balyasny Asset Management L.P. acquired a new position in Sionna Therapeutics in the fourth quarter worth $58,000. BNP Paribas Financial Markets acquired a new position in Sionna Therapeutics in the second quarter worth $31,000. Finally, Mirae Asset Global Investments Co. Ltd. bought a new stake in shares of Sionna Therapeutics during the fourth quarter worth $89,000.

About Sionna Therapeutics

Sionna Therapeutics is a clinical-stage biotechnology company dedicated to developing next-generation RNA therapeutics for oncology and immunology indications. Leveraging proprietary lipid nanoparticle and coacervate delivery technologies, the company aims to overcome key challenges associated with stability, targeting and immune activation that have historically limited the clinical performance of mRNA-based medicines. Its strategic focus spans both solid tumors and hematological malignancies, as well as selected autoimmune disorders, reflecting a broad ambition to harness the power of messenger RNA in diverse therapeutic areas.

At the heart of Sionna’s approach is a platform that combines optimized ionizable lipids with bespoke surface chemistries to enhance payload delivery, intracellular release and endosomal escape.